Europe’s drug regulator has issued a positive opinion for dupilumab in chronic spontaneous urticaria, recommending approval for adults and adolescents 12 and older with moderate-to-severe disease who remain uncontrolled on H1 antihistamines and are naive to anti-IgE therapy. The decision, based on two phase 3 LIBERTY-CUPID studies that reduced itch and hives at 24 weeks versus placebo, sets up a European Commission ruling in the coming months. If approved, dupilumab would become the first new targeted CSU therapy in the EU in more than a decade, adding to its broad immunology footprint across atopic dermatitis, asthma, CRSwNP, EoE, prurigo nodularis, COPD, and bullous pemphigoid.
The strategic signal sits in the label contour. By specifying anti-IgE–naive patients, regulators are implicitly opening a lane for dupilumab as a first biologic option before omalizumab, long the default after high-dose antihistamines. That reordering of the algorithm—if translated into guidelines and payer policy—would mark a notable shift in CSU from an IgE-centric pathway to broader type 2 inflammation control, with implications for clinical workflow, contracting dynamics, and patient segmentation.
For patients, the arrival of a second targeted mechanism could reduce reliance on cyclosporine and other off-label immunosuppressants when antihistamines fail, and may offer at-home administration without the anaphylaxis monitoring historically associated with omalizumab. For physicians across allergy and dermatology, the choice of first biologic will turn on onset, durability, safety profile, administration setting, and comorbid type 2 disease—areas where Medical Affairs will need to deliver clear education and post-approval evidence. For payers, the core question is whether to preserve an omalizumab-first step or permit physician choice at parity, particularly as indication overlap enables multi-indication contracting and as omalizumab biosimilars approach in Europe, potentially compressing net prices.
Commercially, the lack of head-to-head data against omalizumab will put pressure on comparative effectiveness narratives in HTA reviews. Germany’s AMNOG and France’s HAS will test whether dupilumab can secure added-benefit ratings without direct comparisons; in the UK, cost-effectiveness will be judged against entrenched Xolair use patterns. Absent superiority data, expect aggressive contracting from incumbents and a push from Regeneron and Sanofi to leverage dupilumab’s cross-indication scale, home injection convenience, and safety familiarity across more than a million treated patients to secure early formulary access. Real-world studies that clarify responder phenotypes, onset of effect, steroid- or cyclosporine-sparing outcomes, and quality-of-life gains will be critical to payer negotiations and HCP adoption.
The move also tracks a broader industry arc: immunology leaders are extending flagship biologics across adjacent type 2 conditions, using platform science to compound lifetime value while spreading development and field costs. As pipelines thin and capital remains selective, indication stacking on proven assets is becoming the default growth engine. With dupilumab’s recent expansions into COPD and rare dermatoses, a CSU nod would strengthen a franchise built for multi-specialty engagement and indication-based contracting—yet it also concentrates portfolio risk in a single brand battling intensifying price scrutiny across Europe’s evolving HTA landscape.
The next inflection will come not from Brussels but from national access decisions and guideline committees. Will payers and professional societies endorse dupilumab as the first biologic in CSU, or lock in an omalizumab-first step reinforced by biosimilar economics? The first year of launch will be defined by contracting outcomes in Germany and the UK and by the speed and clarity of real-world evidence that justifies a rewired treatment pathway.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
